Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 4;81(11):1217-1223.
doi: 10.1055/a-1533-1651. eCollection 2021 Nov.

Risk of Recurrence in Uterine Leiomyoma with Bizarre Nuclei: a Systematic Review and Meta-Analysis

Antonio Travaglino  1 , Antonio Raffone  2   3 , Angela Santoro  4 , Diego Raimondo  3 , Francesco Paolo Improda  2 , Federica Cariati  5   6 , Margot De Marco  7 , Paolo Casadio  3 , Renato Seracchioli  3 , Fulvio Zullo  2 , Luigi Insabato  1 , Gian Franco Zannoni  3
Affiliations

Risk of Recurrence in Uterine Leiomyoma with Bizarre Nuclei: a Systematic Review and Meta-Analysis

Antonio Travaglino et al. Geburtshilfe Frauenheilkd. .

Abstract
in English, German

Objective Leiomyoma with bizarre nuclei (LBN) is a variant of uterine leiomyoma, which has replaced the previous category of "atypical leiomyoma" and must be distinguished from smooth muscle tumors of uncertain malignant potential (STUMP). However, previously published series of "atypical leiomyoma" might have included both LBN and STUMP, due to the lack of strict diagnostic criteria. Based on such hypothesis, we aimed to define the risk of recurrence in LBN. Study Design A systematic review and meta-analysis was performed by searching 4 electronic databases for all studies assessing the outcome of patients with "atypical leiomyoma" or LBN. The pooled absolute risk of recurrence was calculated. The included studies were subdivided into two subgroups based on the criteria used: "LBN + STUMP" or "LBN-only". Results Twelve studies with 433 patients were included. The pooled risk of recurrence was 5.5% overall. The funnel plot showed two cluster of studies which superimposed to the two subgroups. In the LBN + STUMP cluster/subgroup, the pooled risk of recurrence was 7.7%. In the LBN-only cluster/subgroup, the pooled risk of recurrence was 1.9%. Statistical heterogeneity was null in all analyses. Conclusion Our results show a risk of recurrence of 1.9% for LBN; higher recurrence rates in older studies are likely due to the inclusion of STUMPs.

Zielsetzung Leiomyom mit bizarrem Zellkern (LBN) ist eine Variante von uterinen Leiomyomen, welche die frühere Kategorie „atypisches Leiomyom“ ersetzt; sie sollte von glattmuskulären Tumoren mit unsicherem malignen Potenzial (STUMP) unterschieden werden. Weil aber strenge diagnostischen Kritierien bei früheren Studien fehlten, kann es sein, dass früher veröffentlichte Serien von atypischen Leiomyomen sowohl LBN als auch STUMP umfassen. Basierend auf dieser Hypothese war das Ziel unserer Studie, die Gefahr eines Rezidivs bei LBN zu definieren. Studiendesign Eine systematische Überprüfung und eine Metaanalyse wurden durchgeführt. Hierzu wurden 4 elektronische Datenbanken nach Studien durchsucht, die das Outcome von Patientinnen mit atypischen Leiomyomen bzw. LBN evaluierten. Das gepoolte absolute Risiko eines Rezidivs wurde berechnet. Die eingeschlossenen Studien wurden in 2 Untergruppen unterteilt: eine LBN + STUMP-Gruppe und eine Nur-LBN-Gruppe. Ergebnisse Zwölf Studien mit insgesamt 433 Patientinnen wurden gefunden und evaluiert. Das gepoolte Risiko eines Rezidivs betrug insgesamt 5,5%. Der Funnel Plot zeigte 2 Cluster von Studien, die sich mit den 2 Untergruppen überlagerten. In der LBN + STUMP-Cluster/Untergruppe betrug das gepoolte Risiko für ein Rezidiv 7,7%. In der Nur-LBN-Cluster/Untergruppe betrug das gepoolte Risiko eines Rezidivs dagegen 1,9%. Die statistische Heterogenität betrug bei allen Analysen null. Schlussfolgerung Unsere Ergebnisse zeigen, dass die Gefahr eines Rezidivs bei LBN 1,9% beträgt; die höheren Rezidivraten in älteren Studien beruhen wahrscheinlich auf dem Einschluss von STUMP.

Keywords: diagnosis; leiomyoma; myoma; myomata; prognosis; sarcoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Forest plot reporting the rate or recurrence of published series of so-called “atypical leiomyoma” and leiomyoma with bizarre nuclei, lumped together.
Fig. 2
Fig. 2
Funnel plot for the assessment of the risk of bias across studies. Two different clusters of studies are evident.
Fig. 3
Fig. 3
Forest plot reporting the rate or recurrence in published series of so-called “atypical leiomyoma”.
Fig. 4
Fig. 4
Forest plot reporting the rate or recurrence in published series of leiomyoma with bizarre nuclei.
See this image and copyright information in PMC

References

    1. Mazzei P, Piccolo A, Nugnes L. Metabolic profile of intact tissue from uterine leiomyomas using high-resolution magic-angle-spinning 1 H NMR spectroscopy . NMR Biomed. 2010;23:1137–1145. - PubMed
    1. De Falco M, Staibano S, Mascolo M. Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol. 2009;144:44–47. - PubMed
    1. De Falco M, Staibano S, DʼArmiento F P. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. J Soc Gynecol Investig. 2006;13:297–303. - PubMed
    1. Denschlag D, Ackermann S, Battista M J. Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019) Geburtshilfe Frauenheilkd. 2019;79:1043–1060. - PMC - PubMed
    1. WHO Classification of Tumours Editorial Board Female Genital Tumours Lyon (France)International Agency for Research on Cancer; 2020(WHO classification of tumours series, 5th ed., vol. 4)